2022
Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma
Eugster PJ, Maurer J, Vocat C, Abid K, Matter M, Wuerzner G, Trepp R, Fischli S, Henzen C, Kolb W, Bilz S, Sigrist S, Beuschlein F, Nölting S, Reul A, Schütze I, Hubers SA, Brown NJ, Grouzmann E. Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma. Clinica Chimica Acta 2022, 534: 146-155. PMID: 35905838, DOI: 10.1016/j.cca.2022.07.018.Peer-Reviewed Original ResearchConceptsUpper reference limitPlasma free metanephrinesNeuropeptide YSevere kidney impairmentFree metanephrinesNPY3-36Kidney impairmentSympathetic nervesCatecholamine reuptakeVasoconstrictor peptideNPY2-36NPY1-36Early diagnosisHealthy volunteersPPGL patientsAdrenal medullaTumor localizationPatientsNPYReference limitsDiagnostic sensitivityPPGLsGold standardReference intervalsPheochromocytoma
1999
Clinical Experience Over 48 Years With Pheochromocytoma
Goldstein R, O’Neill J, Holcomb G, Morgan W, Neblett W, Oates J, Brown N, Nadeau J, Smith B, Page D, Abumrad N, Scott H. Clinical Experience Over 48 Years With Pheochromocytoma. Annals Of Surgery 1999, 229: 755. PMID: 10363888, PMCID: PMC1420821, DOI: 10.1097/00000658-199906000-00001.Peer-Reviewed Original ResearchConceptsMicroscopic malignant featuresExtraadrenal pheochromocytomaMalignant diseaseMalignant featuresAdrenal pheochromocytomaSurgical managementMultiple endocrine neoplasia type 2Von Hippel-Lindau diseasePatient's malignant diseaseSame overall survivalLong-term outcomesRate of malignancyKaplan-Meier survival distributionsNumber of patientsVon Recklinghausen's diseaseHippel-Lindau diseaseAreas of controversyCarney syndromeAdrenal tumorsOverall survivalMale patientsFemale patientsBenign diseasePatient survivalFormer tumor